A claudin5-binding peptide enhances the permeability of the blood-brain-barrier

Author:

Trevisani Martina,Berselli Alessandro,Alberini Giulio,Centonze Eleonora,Vercellino Silvia,Cartocci Veronica,Millo Enrico,Ciubanu Dinu Zinovie,Armirotti Andrea,Pisani Francesco,Zara Federico,Castagnola Valentina,Maragliano Luca,Benfenati Fabio

Abstract

ABSTRACTThe blood-brain barrier (BBB) is essential to maintain brain homeostasis and healthy conditions but it also prevents drugs from reaching brain cells. In the BBB, tight junctions (TJs) are multi-protein complexes located at the interface between adjacent brain endothelial cells that regulate paracellular diffusion and claudin-5 (CLDN5) is the major component of the TJ portfolio, playing a pivotal role in restricting the paracellular traffic. In view of obtaining fine control over the transport across the BBB, the use of competing peptides able to bind CLDN5 to induce transient and regulated permeabilization of the paracellular passage is emerging as a potentially translatable strategy for clinical applications. In this work, we designed and tested short peptides with improved solubility and biocompatibility using a combined approach that involved structural modeling techniques andin vitrovalidation, generating a robust workflow for the design, screening, and optimization of peptides for the modulation of the BBB paracellular permeability. We designed a selection of 11- to 16-mer compounds derived from the first CLDN5 extracellular domain and from the CLDN5-binding domain ofClostridium perfringensenterotoxin and determined their efficiency in enhancing BBB permeability. The computational analysis classified all tested peptides based on solubility and affinity to CLDN5, and provided atom-level details of the binding process. From our screening, we identified a novel CLDN5-derived peptide, here calledf1-C5C2, which demonstrated good solubility in biological media, efficient binding to CLDN5 subunits, and capability to increase permeability at low concentrations. The peptidomimeticin silico/in vitrostrategy described here can achieve a transient and reversible permeabilization of the BBB with potential applications in the pharmacological treatment of brain diseases.HIGHLIGHTSWater-soluble peptidomimetics are used to competitively bind claudin-5 tight junction proteins and increase the permeability of the blood-brain barrier;Trans-endothelial electrical resistance and dissociation constant measurements demonstrate the binding affinity of the peptidef1-C5C2for claudin-5;Unbinding free energy calculations correlated with experimental results and provided information on the protein-peptide binding interface.Incubation with the peptidef1-C5C2allows paracellular transport of 4K, but not 70K, dextran.GRAPHICAL ABSTRACT

Publisher

Cold Spring Harbor Laboratory

Reference107 articles.

1. Tight junction modulation of the blood brain barrier: CNS delivery of small molecules;Tissue Barriers,2016

2. The blood-brain barrier: Bottleneck in brain drug development

3. The glucose transporter type 1 (Glut1) syndromes

4. Therapeutic strategies for glucose transporter 1 deficiency syndrome;Ann Clin Transl Neurol,2019

5. Wang D , Pascual JM , Vivo DD (2018) Glucose Transporter Type 1 Deficiency Syndrome, University of Washington, Seattle.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3